实用临床医药杂志2011，Vol.15Issue(19)：105-107,3.
培美曲塞联合奈达铂二线治疗肺腺癌临床观察
Clinical observation of Pemetrexed combined Nedaplatin as second-line treatment for lung adenocarcinoma
摘要
Abstract
Objective To evaluate the curative effect and adverse reaction of Pemetrexed plus Nedaplatin as second - line treatment for lung adenocarcinoma. Methods Thirty - four cases of advanced non - small - cell lung cancer patients were selected, 28 cases who accepted a line chemotherapy failed, 6 patients had received the EGFR - TKI treatment. All patients were performed 2 cycle above Pemetrexed (500 mg/m2, dl) and Nedaplatin (80 mg/m2, dl). Results The overall response rate in the group was 14.1% , No patient had complete response (CR), 5 patients had partial response ( PR) , 16 patients had SD and 13 patients had PD. The 1 - year survival rate was 44. 1% . The median survival time was 10.4 months. Conclusion Pemetrexed combined with Nedaplatin as second - line treatment for lung adenocarcinoma can provide patients with good curative effect, quality of life, and less toxicity reactions. It also has certain curative effect for patients with molecular targeted drug resistance.关键词
培美曲塞/奈达铂/肺腺癌/二线治疗Key words
Pemetrexed/ Nedaplatin/ lung adenocarcinoma/ second-line therapy分类
医药卫生引用本文复制引用
郭刚,陈楠,李高峰,王德光,张继朋,陈瑞彬..培美曲塞联合奈达铂二线治疗肺腺癌临床观察[J].实用临床医药杂志,2011,15(19):105-107,3.基金项目
云南省社会发展重点项目(2010CA015),云南省科技厅联合基金项目(2010CD185) （2010CA015）
